# Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients

> **NCT01989208** · NA · COMPLETED · sponsor: **Sulfagenix Australia Pty Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **OTHER:** SG1002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01989208
- **Lead sponsor:** Sulfagenix Australia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989208, "Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01989208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*